Scarica l'app Stockscreener
3.32
13.99%
-0.54
Precedente Chiudi:
$3.86
Aprire:
$3.8
Volume 24 ore:
291.07K
Relative Volume:
6.62
Capitalizzazione di mercato:
$35.82M
Reddito:
-
Utile/perdita netta:
$-19.09M
Rapporto P/E:
-1.8652
EPS:
-1.78
Flusso di cassa netto:
$-17.24M
1 W Prestazione:
-16.58%
1M Prestazione:
-4.87%
6M Prestazione:
-6.21%
1 anno Prestazione:
-45.93%
Intervallo 1D:
$2.985
$3.84
Intervallo di 1 settimana:
$2.985
$4.461
Portata 52W:
$2.55
$6.7958
Lantern Pharma Inc Stock (LTRN) Company Profile
Nome
Lantern Pharma Inc
Settore
Industria
Telefono
972-277-1136
Indirizzo
1920 MCKINNEY AVENUE, DALLAS, TX
Confronta LTRN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
3.32 | 42.92M | 0 | -19.09M | -17.24M | -1.78 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-10-07 | Iniziato | H.C. Wainwright | Buy |
Lantern Pharma Inc Borsa (LTRN) Ultime notizie
Lantern Pharma outlines commercialization of radar AI modules and expects LP-184 trial enrollment completion by June 2025 - MSN
Lantern Pharma Inc. (NASDAQ:LTRN) Q1 2025 Earnings Call Transcript - MSN
Lake Street to Host Virtual Meeting Featuring LTRN on May 20 | L - GuruFocus
Lantern Pharma Q1 2025 slides: narrowing losses as clinical trials advance - Investing.com Nigeria
Lantern Pharma Advances AI-Driven Cancer Therapies - TipRanks
Lantern Pharma’s Earnings Call: Progress and Prospects - TipRanks
Lantern Pharma Q1 2025 slides: narrowing losses as clinical trials advance By Investing.com - Investing.com South Africa
Transcript : Lantern Pharma Inc., Q1 2025 Earnings Call, May 15, 2025 - marketscreener.com
Lantern Pharma Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:LTRN) - Seeking Alpha
Earnings call transcript: Lantern Pharma Q1 2025 reports narrower loss - Investing.com
Earnings call transcript: Lantern Pharma Q1 2025 reports narrower loss By Investing.com - Investing.com India
Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates | LTRN Stock News - GuruFocus
Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates - BioSpace
Lantern Pharma Reports Q1 2025 Financial Results - TipRanks
Lantern Pharma Inc. SEC 10-Q Report - TradingView
Yaber Highlights the Timeless Design and Natural Aesthetic of the T2 Series in "Lunar Rock" Colorway - Barchart.com
Why Beat Earnings When You Can Just Buy The Dip? - Barchart.com
BIG ROCK BREWERY INC. ANNOUNCES FIRST QUARTER 2025 RESULTS AND 51% INCREASE IN SALES VOLUMES - Barchart.com
The Ordre des arts et des lettres du Québec announces its 2025 cohortTen luminaries will become honorary members on June 9 - Barchart.com
Abigail Disney Urges Donors To Be Braver About Their Giving And Shouldering More Risk - Barchart.com
STATEMENTWith New Federal Health Minister Installed, It's Time To Get To Work: CMA - Barchart.com
Henry Mauriss Calls For A New Era Of Entrepreneurial Innovation In Media - Barchart.com
Phyllis Waud and Rebecca Murray of Syntax Named to CRN's 2025 Women of the Channel List - Barchart.com
Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Tria - GuruFocus
Trump sets 30-day deadline for pharmaceutical companies to lower US drug prices in executive order - Barchart.com
Tino’s Tree Service VA Prioritizes Property Protection with Fully Insured, Expert-Guided Tree Solutions - Barchart.com
Hogs Post Gains On Tuesday - Barchart.com
FDA clears LP-184 trial for NSCLC patients with specific mutations - Investing.com Nigeria
FDA Clears Lantern Pharma's (LTRN) Clinical Trial Amendment for NSCLC Treatment | LTRN Stock News - GuruFocus
Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need - NewsBreak: Local News & Alerts
FDA clears LP-184 trial for NSCLC patients with specific mutations By Investing.com - Investing.com South Africa
EXCLUSIVE: FDA Clears Lantern Pharma's Planned Phase 1b/2 Trial of LP-184 In Treatment-Resistant Lung Cancer Patients - Benzinga
The Conference Of Montreal 2025: Change, Vector Of Opportunities - Barchart.com
Google will pay $1.4 billion to Texas to settle claims the company collected data on users without permission - Barchart.com
Lantern Pharma (LTRN) Gets FDA Clearance for Clinical Trial Targeting Treatment-Resistant, Genomically-Defined Lung Cancer with AI developed LP-184 - Barchart.com
Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET - BioSpace
Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET | LTRN Stock News - GuruFocus
Shootin' The Bull About Holding Ones Breath - Barchart.com
Ion Pure Review: Is IonPure The Best Air Purifier Of 2025? - Barchart.com
Renaissance Technologies LLC Grows Stock Position in Lantern Pharma Inc. (NASDAQ:LTRN) - Defense World
Soybeans Continue Slide On Tuesday - Barchart.com
Pastor Ryan Macdonald Shares His Journey of Faith and Leadership in Exclusive Online Interview - Barchart.com
Entrepreneur Brandon Erickson From Wisconsin Featured In Exclusive Interview Spotlight - Barchart.com
Thinkific Announces First Quarter 2025 Financial Results - Barchart.com
Maneskin Store Launches 2025 Summer Collection For Rock Fans Worldwide - Barchart.com
The End Of The Due Diligence Bottleneck? Valutico’s “Done Diligence” Arrives - Barchart.com
Ma Ai: Driving Singapore’s Digital Future Through Telecommunications Engineering - Barchart.com
Does Cotton Have A Chance To Rally In 2025? - Barchart.com
OSC Analysis Highlights Increasing Mentions And Diverging Sentiment In AI Disclosures - Barchart.com
Nova Scotia Fixed-Term Lease Loophole To Remain In Place Despite Some Abuse: Official - Barchart.com
Corn Slipping Into Midday Trade - Barchart.com
Lantern Pharma Inc Azioni (LTRN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.54%
7.58%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):